Mapi Pharma to launch generic Copaxone next year

Ehud Marom Photo: PR
Ehud Marom Photo: PR

Mapi Pharma has leased a Jerusalem plant, to manufacture delayed release Copaxone that can be taken twice a month.

Israeli drug development company Mapi Pharma, founded and managed by Ehud Marom, former head of Teva's Copaxone development team, announced yesterday that it had rented the Jerusalem plant formerly owned by Omrix Biopharmaceuticals, which closed down most of its activity in Israel. Omrix invested $100,000 in the plant, which has 46,000 square meters. Several months ago, Australian company Aegros announced that it would rent the space, but the deal did not go through.

In the plant, Mapi Pharma will manufacture delayed release Copaxone that can be taken twice a month, instead of twice a week with the current version. A deal for this product has already been signed with Mylan, whose generic version of Copaxone is competing with Teva, the original developer of Copaxone. Mylan invested $20 million in Mapi Pharma, and will invest the same amount by purchasing merchandise in advance. Mapi Pharma will receive a share of Mylan's proceeds from the product.

Mapi Pharma's product is due to enter a Phase III trial in a month, a trial likely to be the last before marketing, after the success of its Phase II trial. Marom says that the Phase II trial results were better than for the original Copaxone. If everything goes according to plan, the launch will be in 2.5-3 years.

Purchase of the plant: Production in preparation for the launch

Why is Mapi Pharma buying a plant now? Marom says, "Today, in order to get FDA approval for a product, you have to show that you're ready to launch it shortly after getting approval. So Mylan already needs a large quantity of the active ingredient now. We're starting to manufacture the ingredient, and Mylan will buy it from us and give us the money in advance, and will financing the investment in the plan and in the production itself."

The Israel Innovation Authority is providing 20% of the budget for the plant. In addition to the plant on Har Hotzvim, which is producing the finished drug, Mapi Pharma has a plant in Neot Hovav that is producing the active ingredient. $8 million has already been invested in the Neot Hovav plant, and $6 million more will be invested in it.

Mapi Pharma also plans to use the plant's surplus production capacity to develop its own generic version of Copaxone in competition with Teva and Mylan, Mapi Pharma's partner. "We'll be in the market in a little more than a year," Marom says.

"Globes": Why do have to enter the competitive generic Copaxone market now, when you're planning on launching a delayed release version in another few years?

Marom: "It's usually worthwhile launching a generic drug if there are up to five competitors in the market, and Copaxone has three now. Each of them is getting $1 billion, and $20 million is enough for me right now. The last to enter is the one who determines the market conditions. Teva ignored us from start to finish. Mylan is a partner, but it's all right for them to see that there's another player in this market."

Mapi Pharma has raised $130 million to date, with Mylan being the leading investor, together with aMoon and Chinese pharma company Zhejiang Jingxin. The company previously started an offering on Nasdaq, but did not get the company value it wanted.

Published by Globes, Israel business news - en.globes.co.il - on July 17, 2019

© Copyright of Globes Publisher Itonut (1983) Ltd. 2019

Ehud Marom Photo: PR
Ehud Marom Photo: PR
Inflation  credit: Tali Bogdanovsky Unexpectedly low February CPI reading cuts inflation

While inflation in Israel in the 12 months to the end of February 2025 is lower than forecast, housing prices continue to rise.

Yitzhak Tshuva credit: Gidon Levy and Tali Bogdanovsky Competition Authority allows Delek takeover of Isracard

The Competition Authority is considered the easier of the two regulatory hurdles that the deal must overcome, the other being the Supervisor of Banks.

David Amsalem  credit  Noam Moskowitz, Knesset Spokesperson's Office Rafael to pay state NIS 444m dividend

The minister in charge of the Government Companies Authority, David Amsalem, has approved the payment by the defense company.

Barak MX air defense system  credit: IAI IAI profit jumps 55%

Israel Aerospace Industries posted a net profit of $493 million for 2024, and ended the year with an all-time high orders backlog of $25 billion.

A TSG system in tactical use  credit: PR TSG signs cooperation agreement with US defense co

The agreement includes the integration of TSG's advanced technologies into sensor-based defense systems, which will be integrated into the operational systems of US defense units.

Bria CEO Yair Adato credit: Kseniia Poliak Israeli visual generative AI co Bria raises $40m

Bria’s Visual Generative AI platform empowers businesses to create predictable, controllable, and on-brand content that aligns with their visual language.

Amnon Shashua and Aviram Ziv credit: Eyal Izhar OrCam stymied by investor dispute with Shashua

Demands by institutional investors are blocking the visual and hearing impairment device developer's recovery plan.

Work on the Green Line credit: Bar Lavi Egged wins tender to operate TA light rail Purple, Green Lines

NTA awarded the tender to Egged, which already operates the Red Line, despite government ministry opposition to one operator for the entire network.

Gabi Seroussi illustration: Gil Gibli Board chooses Seroussi as IAI chair as Erdan freezes candidacy

Israel Aerospace Industries board chose Gabi Seroussi as chair even though he did not to go through the preliminary process of the Government Companies Authority appointments review committee.

Bavli Park penthouse credit: Eyal Tagar Tel Aviv Park Bavli penthouse sells for NIS 43m

A 44th floor penthouse in one of the two towers in businessman Yitzhak Tshuva's Park Bavli project has been bought by an Israeli businessperson.

El Al aircraft  credit: Yoav Yaari El Al pilots receive nearly NIS 250,000 bonus each

Thanks to the agreements signed with the unions in 2018, El Al's employees as well as senior management share in last year's success.

Pentera CEO Amitai Ratzon credit: Eyal Izhar Israeli security validation co Pentera raises $60m

Pentera's platform enables security teams to analyze complete attack paths, identify root causes, and prioritize remediation for effective risk reduction.

Tel Aviv credit: Shutterstock Supply of unsold new homes hits record

Israel's real estate market is sliding into recession with 78,000 unsold new apartments in January, the Central Bureau of Statistics reports.

D&B chairman Doron Cohen and Meitar partner Dan Geva Meitar reclaims title of Israel's biggest law firm

Meitar has first place with 537 lawyers, followed by Herzog Fox Neeman with 512 lawyers, according to the latest Dun's 100 rankings.

First International Bank of Israel CEO Eli Cohen  credit: Eyal Toueg First Int'l posts top return on equity

First International Bank of Israel's return on equity in 2024 was 19%, the highest among Israel's banks.

Dina Ben Tal Ganancia  credit: Guy Kushi & Yariv Fein El Al almost quintuples profit

The airline posted a net profit of $545 million for 2024, 4.7 times the profit in 2023, and an all-time high.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018